Company: JUNS
Filing Date: 2025-11-26
Form Type: S-1
Source: 0001493152-25-025204
Chunk: 161

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-26
Form: S-1
Chunk 161
---
 structural               
 changes in the resveratrol molecule, including glycosylation, alkylation, halogenation, hydroxylation,  
 methylation, and prenylation could lead to the development of derivatives with enhanced bioavailability 
 and pharmacological activity. Resveratrol has never been developed with all the necessary               
 steps to achieve an approval as a pharmaceutical product since the existing natural supplements         
 cannot provide high enough levels of resveratrol in blood plasma to be able to provide a                
 therapeutically effective dose without generating severe gastro-intestinal side effects.                
 This means that we need to take JOTROL™ through the full regulatory NDA (New                            
 Drug Application) requirement to obtain marketing approval. We were able to receive, through            
 a confidential agreement from a major pharmaceutical company, a chronic toxicology study                
 performed with resveratrol, in two different species, that was referenced in our approved               
 Phase I IND application submitted to the FDA. The study was conducted by Charles River Laboratories.    |

| 92 |

| ● | Possible out-licensing for Asian markets is being considered                                                                         
 as it may reduce risk and cost of product development in those markets that requires confirming trials in an Asian population, while 
 generating income through milestones and royalty agreements, see “—Asian Business Development Activities” regarding                  
 further developments and strategy in the Asian market.                                                                               |

Marketing and Commercialization Plan for Therapeutic Drug Candidates

The Company may consider
out-license JOTROL™ for pharmaceutical uses to one or more companies that have such commercialization capability in place.
We may consider at any time a complete exit through any proposed acquisition of our company. In case no acceptable M&A offer is presented
we might consider marketing and distributing JOTROL™ in the USA for the rare disease market only and have companies with
large sales organizations distribute our product for the larger indications. All international distributions will most likely be out-licensed.

The marketing and sales of
orphan drugs can be relatively fast and effective. We believe, based on discussions with organizations such as the EveryLife Foundation
an approval of a drug for a rare disease is efficiently communicated through social media to KOLs, patient advocacy groups and directly
to patients, which may reduce marketing costs.

We are already using information
regarding our development progress through KOLs and the respective patient organizations that exist for each indication. We have also
initiated a collaboration with several patient organizations such as the FARA organization, www.curefa.org, the National MPS